SCHEMBL7197969

SCHEMBL7197969

COCCCCCCCCCCC(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 1.00
TSHR P16473 6/20 0.60
LMNA P02545 2/20 0.60
NFKB1 P19838 1/20 0.60
PMP22 Q01453 1/20 0.60
GPR84 Q9NQS5 8/20 0.54
PPARG P37231 7/20 0.54
PPARD Q03181 7/20 0.54
PPARA Q07869 7/20 0.54
HDAC11 Q96DB2 5/20 0.54
PTPN1 P18031 3/20 0.54
TLR2 O60603 2/20 0.54
TDP1 Q9NUW8 2/20 0.54
FABP4 P15090 2/20 0.54
FFAR1 O14842 2/20 0.54
FFAR4 Q5NUL3 2/20 0.54
SLC22A6 Q4U2R8 1/20 0.54
SLC22A8 Q8TCC7 1/20 0.54
MEN1 O00255 1/20 0.54
ESR1 P03372 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26302700 1.00 ALDH1A1 (1.00) ALDH1A1TSHRLMNANFKB1PMP22
SCHEMBL2553415 1.00 ALDH1A1 (1.00) ALDH1A1TSHRLMNANFKB1PMP22
SCHEMBL849975 1.00 ALDH1A1 (1.00) ALDH1A1TSHRLMNANFKB1PMP22
SCHEMBL1285325 1.00 ALDH1A1 (1.00) ALDH1A1TSHRLMNANFKB1PMP22
SCHEMBL18992918 1.00 ALDH1A1 (1.00) ALDH1A1TSHRLMNANFKB1PMP22
SCHEMBL2556960 1.00 ALDH1A1 (1.00) ALDH1A1TSHRLMNANFKB1PMP22
SCHEMBL3121839 1.00 ALDH1A1 (1.00) ALDH1A1TSHRLMNANFKB1PMP22
SCHEMBL2137289 1.00 ALDH1A1 (1.00) ALDH1A1TSHRLMNANFKB1PMP22
SCHEMBL21655426 1.00 ALDH1A1 (1.00) ALDH1A1TSHRLMNANFKB1PMP22
SCHEMBL7199372 1.00 ALDH1A1 (1.00) ALDH1A1TSHRLMNANFKB1PMP22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0327523-B1 NOVEL FATTY ACID ANALOG ENZYME SUBSTRATES WASHINGTON UNIVERSITY (US) 1992-06-17 EP claimed
EP-0327523-A1 Novel fatty acid analog enzyme substrates WASHINGTON UNIVERSITY (US) 1989-08-09 EP claimed
US-11680034-B2 Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders PTC THERAPEUTICS, INC. (US) 2023-06-20 US disclosed
US-11680034-B2 Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders PTC THERAPEUTICS, INC. (US) 2023-06-20 US disclosed
US-20210238119-A1 FLUOROALKYL, FLUOROALKOXY, PHENOXY, HETEROARYLOXY, ALKOXY, AND AMINE 1,4-BENZOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS PTC THERAPEUTICS, INC. 2021-08-05 US disclosed
CN-113024369-A Compounds for the treatment of oxidative stress disorders PTC医疗公司 2021-06-25 CN disclosed
US-10981855-B2 Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders PTC THERAPEUTICS, INC. (US) 2021-04-20 US disclosed
US-10981855-B2 Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders PTC THERAPEUTICS, INC. (US) 2021-04-20 US disclosed
US-20200331835-A1 FLUOROALKYL, FLUOROALKOXY, PHENOXY, HETEROARYLOXY, ALKOXY, AND AMINE 1,4-BENZOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS PTC THERAPEUTICS, INC. 2020-10-22 US disclosed
US-20200331835-A1 FLUOROALKYL, FLUOROALKOXY, PHENOXY, HETEROARYLOXY, ALKOXY, AND AMINE 1,4-BENZOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS PTC THERAPEUTICS, INC. 2020-10-22 US disclosed
US-10703701-B2 Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders PTC THERAPEUTICS, INC. (US) 2020-07-07 US disclosed
EP-0636134-A1 NOVEL ACYLATED PHOSPHOLIPID DRUGS RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1995-02-01 EP disclosed
WO-1993021191-A1 NOVEL ACYLATED PHOSPHOLIPID DRUGS RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1993-10-28 WO disclosed
EP-0415902-B1 OXY- OR THIO-SUBSTITUTED FATTY ACID ANALOGS FOR USE IN THE TREATMENT OF RETROVIRAL INFECTIONS WASHINGTON UNIVERSITY (US) 1993-03-17 EP disclosed
US-5151445-A Method of inhibiting parasitic activity WASHINGTON UNIVERSITY (US) 1992-09-29 US disclosed
EP-0498783-A2 Method of inhibiting parasitic activity WASHINGTON UNIVERSITY (US) 1992-08-12 EP disclosed
EP-0327523-B1 NOVEL FATTY ACID ANALOG ENZYME SUBSTRATES WASHINGTON UNIVERSITY (US) 1992-06-17 EP disclosed
US-5073571-A Oxy or thio substituted fatty acid or ester WASHINGTON UNIVERSITY (US) 1991-12-17 US disclosed
EP-0415902-A1 Oxy- or thio-substituted fatty acid analogs for use in the treatment of retroviral infections WASHINGTON UNIVERSITY (US) 1991-03-06 EP disclosed
EP-0327523-A1 Novel fatty acid analog enzyme substrates WASHINGTON UNIVERSITY (US) 1989-08-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10703701-B2 Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders NFE2L2, NQO1, ALDH2 ALDH1A1 312/4885TSHR 2889/4885LMNA 505/4885
US-10981855-B2 Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders NFE2L2, NQO1, ALDH2 ALDH1A1 312/4885TSHR 2889/4885LMNA 505/4885
US-20210238119-A1 FLUOROALKYL, FLUOROALKOXY, PHENOXY, HETEROARYLOXY, ALKOXY, AND AMINE 1,4-BENZOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS NFE2L2, NQO1, ALDH2 ALDH1A1 312/4885TSHR 2889/4885LMNA 505/4885
US-11680034-B2 Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders NFE2L2, NQO1, ALDH2 ALDH1A1 312/4885TSHR 2889/4885LMNA 505/4885
US-20200331835-A1 FLUOROALKYL, FLUOROALKOXY, PHENOXY, HETEROARYLOXY, ALKOXY, AND AMINE 1,4-BENZOQUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS NFE2L2, NQO1, ALDH2 ALDH1A1 312/4885TSHR 2889/4885LMNA 505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.